Title	Combination Lucentis and Proton Radiation for Choroidal Melanoma
MEEI Protocol ID	07-06-040
Condition	Choroidal Melanoma
Sponsor	Genentech
Principal Investigator	Ivana Kim, M.D.
Study Design	This is a Phase II singel center, masked, randomized clinical trial.
Study Objective	To evaluate the safety of 2 doses of Lucentis,a medication that is anti-angiogenic and anti-inflammatory, in combination with proton radiation for patients with melanoma of the eye. We will also assess if Lucentis injections may be beneficial for reducting complications due to proton radiation.
Who is Eligible	Individuals with untreated choroidal melanomas that are located near structures that are important for good vision (optic nerve, macula).
Subject Enrollment	We are currently enrolling individuals with eye melanoma who meet all study criteria.
Study Treatment	All qualified participants will receive their first Lucentis injection before they begin a five-day course of proton radiation, which is standard therapy for patients with ocular melanoma. Subsequently, Lucentis injections will be given every two months for two years.
For More Information	Edward Miretsky, Study Coordinator 617-573-4382

Click here to return to the Ophthalmology Clinical Research page.